Vaccines under development could be a solution to breast cancer

Breast cancer, the most common form of cancer in women, can now be fought with new vaccines that are under development. Listeria monocytogenes, a microorganism found in diary products will be used in a new vaccine development program. Dr. Yvonne Paterson, the scientific founder of Advaxis Incorporation and a person who suffered from breast cancer herself, is heading a team of researchers, who are working to develop a new vaccine to fight cancer, using Listeria monocytogenes, which has a direct stimulatory effect on activities of immune killer T cells.

A new vaccine called Lovaxin B has been developed by this team and it is in pre-clinical study and Advaxis Incorporation has sought the approval of FDA for clinical trial of this vaccine. If the vaccine passes the clinical trials, the company plans to manufacture this vaccine in large quantities in future.

Only 20% of people, who are suffering from breast cancer, survive and breast cancer is considered to be a ‘killer disease’ in developing nations. If new initiatives like this one come out well, it would be a great achievement in the field of medicine.

Read more of this story...